Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-08-14 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-07 | Biosergen | Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Biosergen | Biosergen AB: Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Biosergen | Biosergen AB: Biosergen publishes 2022 annual report | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Biosergen AB: Biosergen publishes 2022 annual reportBiosergen CEO Peder M. Andersen commented: ”We are pleased to present Biosergen’s annual report for 2022. The most important event during the year was the successfully repeated dose escalation in our Phase I trial in Australia, which has since been successfully completed earlier this year. The trial was successful in both the single and in the multiple ascending dose part and proved BSG005 to be safe and well tolerated with no serious adverse events and only mild to moderate adverse event (e.g. headache, chills, dizziness). Most importantly it was confirmed that BSG005 does not have any impact on kidney or liver functions and also not on any blood parameters. This is a major advantage compared to Amphotericin B, where kidney problems causes about 30% to stop the treatment with Amphotericin B. Moreover, through our successful rights issue completed in September, we raised more than 42 million SEK, providing us with the necessary funding needed to complete the Phase I trial and initiate and run our recently announced upcoming Phase II trial. The phase II trial will involve patients, who has failed on Amphotericin B for safety reasons and will look for showing efficacy and no safety complications on the kidney and other parameters. Given our pre-clinical data and now clinical phase I data this looks promising and would be a real rescue treatment in patients, with no treatment alternative. Should we be successful in this trial we consider to expand the trial to other countries in order to establish the basis for a regulatory submission and approval for these patients in a ”compassionate use” or ”named patient use” indication. Biosergen will still pursue our already communicated phase II clinical trials. All in all, 2022 was a year of significant progress for us, and we look forward to advancing BSG005’s development with the aim of bringing it to market as a much-needed treatment option for patients with difficult-to-treat fungal infections.” Adjustments have been made in the parent company’s balance sheet regarding the reported value of Shares in subsidiaries. The adjustment refers to a write-down of the shares by SEK 133 million, which has affected the parent company’s Profit after financial items with the corresponding amount. The adjustment has no impact on the cash flow, nor does it have any impact on the Group’s results or financial position. To download the annual report, follow the link https://biosergen.net/investors/filings |
||||
2023-04-28 | Biosergen | Notice of annual general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Reduced risk after positive phase 1-studies - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Minskad risk efter positiva fas 1-studier - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for fourth quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Carlsquare | Carlsquare: Mrkt BUZZ, Biosergen: Plans for speedy development of lead candidate | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Biosergen | Biosergen AB: Biosergen provides Phase 2 clinical development strategy update | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-28 | Biosergen | Biosergen AB: Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Biosergen will be participating at Mangold Insight Investor Day, March 22 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Carlsquare has initiated its coverage of Biosergen | Pressreleaser | Visa Stäng |
|
||||
2023-03-20 | Carlsquare | Carlsquare: Initiation of coverage, Biosergen: Make antifungals great again | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-13 | Biosergen | Biosergen AB: Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Fungicide with potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Svampdödare med potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-16 | Biosergen | Biosergen AB: Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-12-12 | Biosergen | Biosergen AB: The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-30 | Biosergen | Biosergen AB: Biosergen publishes interim report for third quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-10-20 | Biosergen | Biosergen AB: Biosergen's warrants of series TO2 are admitted to trading | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-19 | Biosergen | Biosergen AB: Biosergen allocates shares to an underwriter in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-05 | Biosergen | Biosergen AB: Biosergen appoints Mangold Fondkommission to act as a liquidity provider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-04 | Biosergen | Biosergen AB: Biosergen announces the outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-26 | Biosergen | Biosergen AB: Mangold Insight publishes interview with Biosergen's CEO | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-22 | Biosergen | Biosergen AB: Members of the board of directors and executive management subscribe in ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Biosergen | Biosergen AB: The subscription period in Biosergen's rights issue starts today | Pressreleaser | Visa Stäng |
|
||||
2022-09-08 | Biosergen | Biosergen AB: Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-02 | Biosergen | Biosergen AB: Biosergen's Board of Directors decides on a rights issue of units of approximately SEK 60.2 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for second quarter 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen receives a loan of SEK 7 million to finance continued development | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Biosergen | Biosergen AB: Biosergen completes the third cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|